Kalaris Therapeutics, Inc. (KLRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.49M
Last updated: Nov 17, 2026 at 11:05 AM ET
Kalaris Therapeutics, Inc. (KLRS) Stock Forecast
Analysts expect Kalaris Therapeutics (KLRS) to earn -$1.92 per share in the fiscal year ending Dec 31, 2026. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 5 | 62.5% |
| Hold | 1 | 12.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.92
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.63
- EPS consensus, revenue $13.33M
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.92 | -$1.97 to -$1.87 | 5 | N/A | N/A | 7 |
| Dec 31, 2027 | -$1.63 | -$2.29 to $0.70 | 8 | $13.33M | N/A | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.52 for the quarter ending Dec 31, 2026 to -$0.59 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.52 | -$0.56 to -$0.49 | 10 |
| Mar 31, 2027 | -$0.59 | -$0.66 to -$0.53 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.01.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.92 | -$2.00 | -$2.00 | -$2.01 | -$2.01 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.63 | -$1.65 | -$1.65 | -$1.66 | -$1.66 | N/A |
| Quarter ending Mar 31, 2027 | -$0.59 | -$0.55 | -$0.55 | -$0.55 | -$0.55 | N/A |
Frequently Asked Questions About KLRS
What is the KLRS stock forecast?
Consensus analyst estimates put Kalaris Therapeutics's EPS at -$1.92 for the fiscal year ending Dec 31, 2026. The consensus rating from 8 analysts is Buy.
How do analysts rate KLRS stock?
Of 8 analysts covering Kalaris Therapeutics, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KLRS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.92, with estimates from -$1.97 to -$1.87 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.63, with estimates from -$2.29 to $0.70 from 8 analysts.
What revenue do analysts expect from Kalaris Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $13.33M.
How many analysts cover KLRS?
8 analysts rate Kalaris Therapeutics stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KLRS pages: Overview, Earnings, Forecast, Financials, Competitors